Charles River Laboratories (CRL)

• Market cap: $8.36B
• 1 day: -1.39%
• 5 days: -12.26%
• 1 month: -13.64%
• 3 months: -17.33%
• 6 months: -26.73%
• Year to date: -10.48%
• 1 year: -19.66%
• 5 years: 2.33%
• 10 years: 139.88%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.35% less ownership

Funds ownership: 103.7% [Q2] → 101.36% (-2.35%) [Q3]

6% less funds holding

Funds holding: 657 [Q2] → 616 (-41) [Q3]

7% less capital invested

Capital invested by funds: $11B [Q2] → $10.3B (-$769M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]

26% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 268

32% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 97

38% less call options, than puts

Call options by funds: $59M | Put options by funds: $94.8M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $167 2% upside
• Avg. target: $211 29% upside
• High target: $250 53% upside

6 analyst ratings

• positive: 1 17%
• neutral: 4 67%
• negative: 1 17%

UBS Dan Leonard 29% 1-year accuracy 2 / 7 met price target	13% upside $185	Neutral Downgraded	17 Jan 2025
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target	28% upside $210	Neutral Maintained	13 Dec 2024
TD Cowen Charles Rhyee 30% 1-year accuracy 3 / 10 met price target	39% upside $227	Hold Maintained	11 Nov 2024
UBS Dan Brennan 41% 1-year accuracy 12 / 29 met price target	53% upside $250	Buy Maintained	7 Nov 2024
Evercore ISI Group Ross Muken 0% 1-year accuracy 0 / 5 met price target	38% upside $225	In-Line Maintained	7 Nov 2024